Digitální knihovna UPCE přechází na novou verzi. Omluvte prosím případné komplikace. / The UPCE Digital Library is migrating to a new version. We apologize for any inconvenience.

Publikace:
Importance of Mesoporous Silica Particle Size in the Stabilization of Amorphous Pharmaceuticals-The Case of Simvastatin

Článekopen accesspeer-reviewedpublished version
dc.contributor.authorKnapik-Kowalczuk, Justynacze
dc.contributor.authorKramarczyk, Danielcze
dc.contributor.authorChmiel, Krzysztofcze
dc.contributor.authorRomanová, Janacze
dc.contributor.authorKawakami, Kohsakucze
dc.contributor.authorPaluch, Mariancze
dc.date.accessioned2021-05-15T18:21:01Z
dc.date.available2021-05-15T18:21:01Z
dc.date.issued2020eng
dc.description.abstractIn this paper, the role of mesoporous silica (MS) particle size in the stabilization of amorphous simvastatin (SVT) is revealed. For inhibiting recrystallization of the supercooled drug, the two MS materials (Syloid((R)) XDP 3050 and Syloid((R)) 244 FP) were employed. The crystallization tendency of SVT alone and in mixture with the MS materials was investigated by Differential Scanning Calorimetry (DSC) and Broadband Dielectric Spectroscopy (BDS). Neither confinement of the SVT molecules inside the MS pores nor molecular interactions between functional groups of the SVT molecules and the surface of the stabilizing excipient could explain the observed stabilization effect. The stabilization effect might be correlated with diffusion length of the SVT molecules in the MS materials that depended on the particle size. Moreover, MS materials possessing different particle sizes could offer free spaces with different sizes, which might influence crystal growth of SVT. All of these factors must be considered when mesoporous materials are used for stabilizing pharmaceutical glasses.eng
dc.description.abstract-translatedPráce studuje roli mezoporézní siliky pro stabilizaci amorfního léčiva Simvastatin. Inhibice rekrystalizace je sledována metodami DSC a BDS.cze
dc.format"384-1"-"384-21"eng
dc.identifier.doi10.3390/pharmaceutics12040384eng
dc.identifier.issn1999-4923eng
dc.identifier.obd39884914eng
dc.identifier.scopus2-s2.0-85083742684
dc.identifier.urihttps://hdl.handle.net/10195/77079
dc.identifier.wos000535575000089eng
dc.language.isoengeng
dc.peerreviewedyeseng
dc.publicationstatuspublished versioneng
dc.publisherMDPIeng
dc.relation.ispartofPharmaceutics, volume 12, issue: 4eng
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/12/4/384eng
dc.rightsopen access (CC BY 4.0)eng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectsimvastatineng
dc.subjectamorphous pharmaceuticalseng
dc.subjectmesoporous silicaeng
dc.subjectstabilizationeng
dc.subjectrecrystallizationeng
dc.subjectsimvastatincze
dc.subjectamorfní léčivacze
dc.subjectmezoporézní silikacze
dc.subjectstabilizacecze
dc.subjectrekrystalizacecze
dc.titleImportance of Mesoporous Silica Particle Size in the Stabilization of Amorphous Pharmaceuticals-The Case of Simvastatineng
dc.title.alternativeDůležitost velikosti částic mezoporézní siliky pro stabilizaci amorfních léčiv - Případ Simvastatincze
dc.typeArticleeng
dspace.entity.typePublication

Soubory

Původní svazek

Nyní se zobrazuje 1 - 1 z 1
Načítá se...
Náhled
Název:
Knapik-pharmaceutics-12-00384-v2.pdf
Velikost:
7.43 MB
Formát:
Adobe Portable Document Format